International journal of antimicrobial agents · 2026
Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter pylori Eradication: A Real-World Evidence Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ju Kunping, Sun Longfei, Guo Yuting, Zhang Lili, Liu Fengqing, Zhai Zhenzhen, Zhao Hongyu, Li Ruili, Wang Baobao, Duan Miao, Kong Qingzhou, Li Yueyue, Zuo Xiuli, Li Yanqing
Аннотация
OBJECTIVES: This study aimed to evaluate the efficacy and safety of various bismuth-containing quadruple therapies (BQTs) with potassium-competitive acid blockers (P-CABs) for Helicobacter pylori eradication.
METHODS: This multicenter retrospective cohort study evaluated 1730 treatment-naïve patients receiving P-CABs-based BQTs (P-BcQT). The regimens consisted of one P-CAB (vonoprazan or tegoprazan), bismuth, and two antibiotics including amoxicillin, clarithromycin, levofloxacin, tetracycline and cefuroxime, with a treatment duration of 10 to 14 days. We comprehensively assessed eradication rates, adverse events, and risk factors predictive of positive results. Receiver operating characteristic curve analysis identified optimal cut-off values for predicting outcomes, while multivariate regression determined independent predictors of treatment failure and adverse events.
RESULTS: The overall eradication rate was 92.3% and 92.9% by modified intention-to-treat and per-protocol analysis, respectively. Multivariate analysis revealed three independent predictors of failure: high body surface area (BSA ≥1.76 m²) (OR: 1.545, 95% CI: 1.010-2.362, P = 0.045), low compliance (OR: 3.442, 95% CI: 1.891-6.266, P < 0.001), and suboptimal antibiotic combinations. Especially, amoxicillin/clarithromycin (P = 0.005) and cefuroxime/levofloxacin regimens (P < 0.001) demonstrated significantly higher failure trend compared to amoxicillin/tetracycline combinations. The adverse event rate was 26.9%, with lower body mass index (BMI <28.38 kg/m²) (P = 0.011) and long treatment duration (P = 0.007) emerging as independent risk factors. Overall compliance was excellent (95.6%).
CONCLUSIONS: P-BcQT demonstrated promising efficacy as a first-line H. pylori treatment regimen. However, regimens containing clarithromycin or levofloxacin appear less effective. Future optimization may focus on shorter treatment durations, personalized dosing adjustments and regional resistance patterns.
METHODS: This multicenter retrospective cohort study evaluated 1730 treatment-naïve patients receiving P-CABs-based BQTs (P-BcQT). The regimens consisted of one P-CAB (vonoprazan or tegoprazan), bismuth, and two antibiotics including amoxicillin, clarithromycin, levofloxacin, tetracycline and cefuroxime, with a treatment duration of 10 to 14 days. We comprehensively assessed eradication rates, adverse events, and risk factors predictive of positive results. Receiver operating characteristic curve analysis identified optimal cut-off values for predicting outcomes, while multivariate regression determined independent predictors of treatment failure and adverse events.
RESULTS: The overall eradication rate was 92.3% and 92.9% by modified intention-to-treat and per-protocol analysis, respectively. Multivariate analysis revealed three independent predictors of failure: high body surface area (BSA ≥1.76 m²) (OR: 1.545, 95% CI: 1.010-2.362, P = 0.045), low compliance (OR: 3.442, 95% CI: 1.891-6.266, P < 0.001), and suboptimal antibiotic combinations. Especially, amoxicillin/clarithromycin (P = 0.005) and cefuroxime/levofloxacin regimens (P < 0.001) demonstrated significantly higher failure trend compared to amoxicillin/tetracycline combinations. The adverse event rate was 26.9%, with lower body mass index (BMI <28.38 kg/m²) (P = 0.011) and long treatment duration (P = 0.007) emerging as independent risk factors. Overall compliance was excellent (95.6%).
CONCLUSIONS: P-BcQT demonstrated promising efficacy as a first-line H. pylori treatment regimen. However, regimens containing clarithromycin or levofloxacin appear less effective. Future optimization may focus on shorter treatment durations, personalized dosing adjustments and regional resistance patterns.